Dr Reddy Laboratories Ltd is expected to provide Phase 3 trial data for its single-dose Russian COVID-19 vaccine Sputnik Light to India’s Medicines Regulatory Authority next month, even as the city-based company prepares to conduct trials of the vaccine on 2-18 One-year-olds in two groups. Deepak Sapra CEO API and Services Dr.

He also said Dr. Reddy is trying to enter into discussions with Sputnik V Center for Government Supplies even as the company sees a softness in taking the vaccine in the private sector. As far as the Sputnik Light is concerned, we’re in the midst of our clinical trials and expect to be able to have an update beyond our submission to DCGI in November.

As far as a booster dose of Sputnik is concerned, we are done with our protocol. We are in discussions with DCGI to begin trials for the Sputnik booster dose, Sabra said at a virtual press conference. He added that in addition to serving the Indian requirements, Dr. Reddy is in discussions with her partners to take the jab to other countries particularly in Asia Pacific, Africa and Latin America.

The official said that we are seeing a softness in the immediate launch of the vaccine in the private sector in India. In accordance with the recommendations of the Securities and Exchange Commission (SEC) meeting held last August, Dr. Reddy, who was associated with the Russian Direct Investment Fund to market the vaccine in India, provided updated data on the safety, immunogenicity and efficacy of the phase III clinical trial of the Sputnik Lite vaccine that was conducted. In Russia, along with a proposal to conduct a clinical trial in India.

Sabra explained that trials of Sputnik as a booster dose and a pediatric dose are being conducted by RDIF outside India, adding that trials in India may kick off in November.

Read all the latest news, breaking news and coronavirus news here. Follow us Facebook social networking siteAnd Twitter And cable.

Source link

By admin

Leave a Reply

Your email address will not be published.